SCHEMBL612073

SCHEMBL612073

COc1ccc2c(c1OC)CC(c1ccccc1)C1CC(=O)NCC21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 9/20 0.41
PDE4B Q07343 5/20 0.41
PDE4C Q08493 5/20 0.41
PDE4D Q08499 5/20 0.41
ADRA2A P08913 1/20 0.38
DRD2 P14416 1/20 0.38
ADRA2B P18089 1/20 0.38
ADRA2C P18825 1/20 0.38
DRD1 P21728 1/20 0.38
DRD5 P21918 1/20 0.38
DRD3 P35462 1/20 0.38
ACHE P22303 1/20 0.37
SIRT1 Q96EB6 1/20 0.37
PARP1 P09874 1/20 0.36
TSHR P16473 1/20 0.36
MAPT P10636 2/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA4 P22748 1/20 0.36
CA7 P43166 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL612977 0.80 ADRA2A (0.60) ADRA2ADRD2ADRA2BADRA2CDRD1
SCHEMBL613222 0.74 PARP1 (0.46) PDE4APDE4BPDE4CPDE4DACHE
SCHEMBL612710 0.74 PARP1 (0.46) PDE4APDE4BPDE4CPDE4DACHE
SCHEMBL612709 0.74 PARP1 (0.46) PDE4APDE4BPDE4CPDE4DACHE
SCHEMBL613221 0.74 PARP1 (0.46) PDE4APDE4BPDE4CPDE4DACHE
SCHEMBL10875813 0.72 PARP3 (0.43) ADRA2ADRD2ADRA2BADRA2CDRD1
SCHEMBL9038554 0.69 KDM4E (0.35) PDE4APDE4BPDE4CPDE4DACHE
SCHEMBL11710269 0.68 PDE4A (0.58) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL9038809 0.68 SIRT1 (0.34) PDE4APDE4BPDE4CPDE4DSIRT1
SCHEMBL7304489 0.68 KDM1A (0.39) TUBB4ATUBBTUBA3CTUBA1BTUBA4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9359303-B2 Octahydrobenzoisoquinoline modulators of dopamine receptors and uses therefor PURDUE RESEARCH FOUNDATION (US) 2016-06-07 US disclosed
EP-2421862-B1 OCTAHYDROBENZOISOQUINOLINE MODULATORS OF DOPAMINE RECEPTORS AND USES THEREFOR PURDUE RESEARCH FOUNDATION (US) 2014-06-11 EP disclosed
US-20120041018-A1 OCTAHYDROBENZOISOQUINOLINE MODULATORS OF DOPAMINE RECEPTORS AND USES THEREFOR PURDUE RESEARCH FOUNDATION (US) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120041018-A1 OCTAHYDROBENZOISOQUINOLINE MODULATORS OF DOPAMINE RECEPTORS AND USES THEREFOR DBH, SLC6A3, SLC18A2 PDE4A 285/4885PDE4B 280/4885PDE4C 402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.